Background: A high prevalence of cannabis use disorder has been reported in subjects suffering from schizophrenia, fueling intense debate about whether schizophrenia with pre-onset cannabis use disorder may be a…
Keyword: schizophrenia
Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids
The aim of this article is to summarize current evidence regarding alterations in the neuroendocrine stress response system and endocannabinoid system and their relationship in psychotic disorders such as schizophrenia….
Brain CB2 Receptors: Implications for Neuropsychiatric Disorders
Although previously thought of as the peripheral cannabinoid receptor, it is now accepted that the CB2 receptor is expressed in the central nervous system on microglia, astrocytes and subpopulations of…
Cannabidiol as a potential treatment for psychosis
Abstract Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the…
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels…
Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice
Cannabidiol, a nonpsychoactive constituent of the Cannabis sativa plant, has been reported to act as an agonist of the vanilloid 1 channel in the transient receptor potential family (TRPV1) and…
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Abstract A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD),…
Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders
Endocannabinoids and their receptors, mainly the CB1 receptor type, function as a retrograde signaling system in many synapses within the CNS, particularly in GABAergic and glutamatergic synapses. They also play…
The Development of Cannabidiol as a Psychiatric Therapeutic: A Review of Its Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms
Cannabidiol (CBD), a once-considered inert cannabis constituent, is one of two primary constituents of cannabis, alongside delta-9-tetrahydrocannabinol (∆9-THC/THC). In the last 30 years, CBD has become implicated with a range…